locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel
Non-small cell lung cancer, KRAS mutation, KRAS G12C, Next-generation sequencing, Tumor burden, PD-L1 expression
Tertiary lymphoid structures, Lung adenocarcinoma, PD-L1 expression, Tumor mutation burden, Gene expression analysis